- A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancerDing, K.; Liu, Y.; Song, Y.; Xu, D.; Li, J.; Wang, J.; Chen, X.; Lin, R.; Jiang, Y.; Zhang, Y.; Zhang, W.; Cheng, Y.; Wu, X.; Yuan, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ? Bevacizumab versus FOLFOX ? Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Wang, Feng; He, Ming -Ming; Xiao, Jian; Zhang, Yan-Qiao; Yuan, Xiang-Lin; Fang, Wei-Jia; Zhang, Yan; Wang, Wei; Hu, Xiao-Hua; Ma, Zhi-Gang; Yao, Yi-Chen; Zhuang, Zhi-Xiang; Zhou, Fu-Xiang; Ying, Jie-Er; Yuan, Ying; Zou, Qing-Feng; Guo, Zeng-Qing; Wu, Xiang-Yuan; Jin, Ying; Mai, Zong-Jiong; Wang, Zhi-Qiang; Qiu, Hong; Guo, Ying; Shi, Si -Mei; Chen, Shuang-Zhen; Luo, Hui-Yan; Zhang, Dong-Sheng; Wang, Feng-Hua*; Li, Yu-Hong; Xu, Rui-Hua*Clinical Cancer Research, 2022, 28(19): 4232-4239.被引 6
- CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.Xu, Jianming; Cao, Bangwei; Gu, Kangsheng; Bai, Yuxian; Li, Wei; Zhang, Jingdong; Liu, Caigang; Niu, Zuoxing; Zhang, Liangming; Zhong, Haijun; Luo, Suxia; Zhou, Jian-Wei; Liu, Tianshu; Gu, Yanhong; Lin, Jingguan; Deng, Yanhong; Chen, Chuangqi; Li, Yunfeng; Yang, Xiuli; Li, BihuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
10阅读
